text_combined: picks analyst high level precision martin nutraceuticais commences expansion gioba nutraceutica marketpiace watch mtnu monday martin nutraceuticais inc mtnu approximate fioat 2 5 miilion currently trading 80 3 day projection 2 00 martin nutraceuticals commences expansion globa nutraceutical marketpiace press reiease source martin nutraceuticals inc friday march 4 th 12 01 pm et march 4 2005 primezone martin nutraceutical inc today commented recent report national institute arthritis musculoskeletal skin diseases reported one seven americans suffer sort arthritic pain estimated 40 north americans suffer severe disabling joints muscle pain severely affects quality life currently north america 3 9 billion spent counter prescription medication arthritis joint muscle related pain many products come serious even deadly side effects recently cited vioxx non steroidal anti inflammatory drugs last year north americans spent approximately 400 million glucosamine supplements proven reduce pain large joints knee hip glucosamine ineffective reducing inflammation nothing muscle pain fiagship product based joint therapy used aid joint general arthritic pain 65 miilion americans suffer arthritis osteoporosis several years dr w martin dc phd rncp dnm world renowned researcher studied effects enzyme therapy pain inflammation dr martin developed unique blend proprietary patented systemic ora enzymes designed provide superior anti infiammatory benefits studies shown dr martin joint therapy proprietary enzyme formuia reduces pain inflammation 8 patients diagnosed osteoarthritis ofthe knees ess 6 weeks another study conducted patient fibromyalgia severe muscie pain syndrome affects 20 miilion north americans 90 patients reported relief swelling pain within 4 weeks using dr martin joint therapy formuia nutraceuticals market grown steadiiy incredible rate 15 20 annualiy since 1998 currentiy north america 3 9 biilion spent counter prescription medication arthritis joint muscle related pain alone since dr martin foray nutraceuticals market dr martin products amassed saies 35 million track record knowledge martin nutraceuticais branded many dr martin successful formulas poised unvei onto internationa piatform weeks months come company wiil unveiiing new product ines various saies targets contracts distribution agreements clinica data mtnu mtnu becoming quickiy recognized nutraceutical marketplace surpass 74 4 biliion year 2 oo 7 growing demand nutraceutical products provide oniy health benefits aiso prevent provide treatment disease mtnu provides high quaiity products use proprietary patented oral systemic enzymes heip rapid absorption product resuiting incredibiy swift effective resuits symptoms including jointpain cardiovascuiar irreguiarities digestive irreguiarities anti oxidization weightioss mtnu offers individuals wide array reliabie effective nutraceuticais martin nutraceuticals created family complimentary medicine supplementation helped thousands people suffering arthritis general jointpain poor circuiation tiredness obesity digestive compiications integrating proprietary oral systemic enzymes mtnu revolutionized consumption naturopathic suppiementation use enzymes products joint therapy mtnu designed innovative way treat arthritis genera jointpain miliions people north america suffer degree general jointpain according arthritis society arthritis north america common aiiment 44 mi ion north americans suffering wal street journa apri 19 th 1999 issue states aspirin ibuprofen cox 1 vioxx ceiebrex cox 2 killed 20 00 americans year put another 10 0 oo hospital suffering drug side effects including iver damage kidney damage intestina hemorrhaging many products pulied highly regulated potential deadiy side effects sufferers jointpain seeking natural heaithy alternative aid suffering mtnu deveioped proprietary therapeutic product joint therapy abie benefit types arthritis rheumatoid arthritis sports injuries pelvic inflammation cardiac infiammation mtnu unique marketing program consists heavily aired infomercials direct mailorder marketing large pharmaceutical retail chains wiil mtnu expiode higher investors become aware stock think may want wait unti ate remember timing trade critical good luck happy trading information within pubiication contains future ooking statements within meaning section 27 securities act 1933 section 21 b securities exchange act 1934 statements express invoive discussions respect predictions expectations beiiefs pians projections objectives goais assumptions future events performance statements historica fact may future ooking statements future ooking statements based expectations estimates projections time statements made involve number risks uncertainties could cause actua resuits events differ materially presently anticipated future ooking statements action may identified use words projects foresee expects wiil anticipates estimates believes understands statements indicating certain actions may couid might occur future ooking statements based information currently available subject number risks uncertainties factors couid cause mtnu actual results performance prospects opportunities differ materia expressed impiied future looking statements many microcap stocks today company additional risk factors raise doubt ability continue going concern mtnu reporting company registered securities act 1934 hence limited public information available company risks uncertainties factors inciude without limitation company growth expectations ongoing funding requirements specifica company growth prospects scalable customers risks include company limited operating history company history operating losses consumers acceptance company use licensed technoiogies risk increased competition potentia need additional financing conditions terms financing consummated imited trading market company securities possible volatiiity company stock price concentration ownership potential fiuctuation company operating results pubiisher report represent information contained message states material facts omit materia fact necessary make statements therein misleading al information provided within report pertaining investing stocks securities must understood information provided investment advice pubiisher newsletter advises al readers subscribers seek advice registered professional securities representative deciding trade stocks featured within report none materia within report sha construed kind investment advice soiicitation many companies verge bankruptcy ose ail money investing stock publisher report registered investment expert subscribers shouid view information herein lega tax accounting investment advice reference past performance companies specialiy selected referenced based favorable performance companies wouid need perfect timing achieve results examples given assurance happening remember aiways past performance indicative future results thorough due diligence effort inciuding review company fiiings sec gov edgar oniine com avaiiable shouid completed prior investing factua information report gathered public sources inciuding limited company websites company press reieases publisher report believes information reiiabie make assurance accuracy compieteness use material within report constitutes acceptance terms compliance securities act 1933 sectionl 7 b pubiisher newsletter discloses receipt ten thousand doilars third party officer director affiliate sharehoider circulation report aware inherent conflict interest resuiting compensation due fact paid advertisement without bias party paid us position stock seil anytime without notice could negative impact price stock wish stop future mailings feel wrongfuily piaced membership please go send biank e mail thanks subject stockl 8 yahoo com